Meeting
2018 Genitourinary Cancers Symposium
Experience of a Brazilian oncological center using abiraterone acetate in metastatic castration-resistant prostate cancer patients.
Authors
Daniel D`Almeida Preto
Barretos Cancer Hospital, Barretos, Brazil
Daniel D`Almeida Preto , Luis Eduardo Zucca , Flavio Mavignier Carcano , Ricardo Zylberberg , Joao Antonio Junior Neif , Carlos Alberto Fruet Filho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 364)
DOI
10.1200/JCO.2018.36.6_suppl.364
Abstract #
364
Poster Bd #
E11
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.
First Author: Syed A. Hussain
Poster
2016 ASCO Annual Meeting
Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).
First Author: Johann S. De Bono
Poster
2015 Genitourinary Cancers Symposium
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France.
First Author: Nadine Houede
Poster
2014 Genitourinary Cancers Symposium
Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
First Author: Arun Azad